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Abstract
Background: The objective of this study was to investigate the prognostic and predictive significance of tumor
length in patients with esophageal squamous cell carcinoma undergoing radical resection.
Methods: Tumor length and other clinicopathological variables were retrospectively evaluated in 1435 patients
with squamous cell carcinoma treated with radical resection between 2003 and 2010. Tumor length was analyzed
as categorical and continuous variable. Associations with overall survival were assessed with Cox proportional
hazards models. Model-based nomograms were constructed. Predictive accuracy was measured with C-index.
Decision curve analysis was used to evaluate clinical usefulness of prediction models.
Results: Both categorically and continuously coded tumor length were independent prognostic factors in
multivariable analysis. Adding categorically and continuously coded tumor length to TNM staging model increased
predictive accuracy by 0.2 and 0.4 % respectively. Decision curve analysis revealed that the models built by the
addition of categorically or continuously coded tumor length did not perform better than TNM staging model.
Conclusions: Tumor length is an independent prognostic factor in patients with esophageal squamous cell
carcinoma treated with radical resection. It increases predictive accuracy of TNM staging system for overall survival
in these patients. But it does not increase clinical usefulness of TNM staging system as a prediction model.
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Background
Esophageal cancer is one of the most aggressive malig-
nancies throughout the world with the sixth highest can-
cer deaths annually [1]. The tumor, node, metastasis
(TNM) staging system is an important tool to assess
prognosis, guide therapy, formulate treatment protocols
and promote the exchange of information between dif-
ferent centers [2]. In the current 7th edition of American
Joint Committee on Cancer (AJCC) TNM staging system,
histological grading, tumor location as well as depth of
esophageal wall invasion are used for stage grouping for
squamous cell carcinoma [3]. Recently some authors
found tumor length was an independent prognostic factor
for esophageal cancer [4–11], and even suggested incorp-
orating tumor length into TNM staging system to identify
high-risk patients for postoperative therapy [4–9]; while
others did not find any associations between tumor length
and long-term survival in patients with esophageal cancer
[12–15]. Therefore the prognostic role of tumor length
still needs to be ascertained. On the other hand, whether
incorporating tumor length into TNM staging system
could generate a better prediction model for outcomes of
esophageal cancer patients also requires to be further in-
vestigated. The purpose of this study was to evaluate the
prognostic and predictive significance of tumor length in
patients with esophageal squamous cell carcinoma treated
with radical resection within a single institution.
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This study was approved by the institutional review
board of Zhejiang Cancer Hospital and the need for
individual patient consent was waived. The study was
conducted with data collected from a prospectively col-
lected database for esophageal cancer. Between January
2003 and December 2010, 1613 consecutive cases were
surgically treated at the Department of Thoracic Surgery
of Zhejiang Cancer Hospital. Because an institutional
electronic medical record system was used in our hos-
pital since January 2003, this date was chosen as the
starting date for the study. A total of 1435 patients with
esophageal squamous cell carcinoma after resection with
curative intent were included in this study (Fig. 1).
Among 47 patients excluded because of incomplete re-
section, 35 patients had macroscopic residual disease
(R2 resection) and 12 patients had microscopic disease
(R1 resection: positive proximal resection margin in nine
cases and positive distal resection margin in three cases).
Seventeen patient with previous cancer history (gastric
cancer in eight cases, lung cancer in four cases, laryngeal
caner in three cases, breast cancer in one cases and ma-
lignant lymphoma in one cases) were excluded. Of 12
patients excluded because of synchronous cancer, seven
patients had synchronous gastric cancers, three patients
Fig. 1 Flow chart of study population
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had synchronous hypopharyngeal cancers, one patient
had a synchronous laryngeal cancer, and one patient
had synchronous leukemia. Sixteen patients with non-
squamous carcinoma (adenocarcinoma in six cases,
adenosquamous carcinoma in four cases, small cell
carcinoma in four cases, and carcinosarcoma in two
cases) were also excluded. Because neoadjuvant ther-
apy may influence postoperative pathological staging
and tumor length, patients with neoadjuvant therapy
were excluded. All of these 1435 patients received
preoperative evaluations including endoscopy with biopsy,
barium swallow examination, computerized tomography
of the chest and upper abdomen, and ultrasound of the
neck. Pulmonary and cardiac function tests were routinely
performed to assess medical operability. Recurrent laryn-
geal nerve palsy and the presence of clinical supraclavicu-
lar or cervical nodal involvement were considered a
contraindication for surgery. Histological diagnosis of each
of the patients was established before treatment. Written
informed consents were obtained from all patients before
surgery.
Surgical procedure
Three surgical approaches were commonly used: Ivor
Lewis procedure, cervico-thoraco-abdominal approach
(Mckeown prodcedure), and left thoracotomy approach
(Sweet procedure). Ivor Lewis procedure and Sweet pro-
cedure with anastomosis in the chest apex were usually
performed when the tumor located in the lower and
middle segment of the esophagus. When the tumor lo-
cated in the middle or upper segment of the esophagus,
Mckeown procedure with anastomosis in the left neck
was mainly conducted (Fig. 1). Meanwhile, the choice of
surgical procedure also depended on surgeons’ prefer-
ences. Two-field (mediastinal and upper abdominal)
lymph node dissection was routinely performed for all
patients. The extent of mediastinal lymph node dis-
section included all nodal tissue associated with
esophagus in the chest from the superior mediastinal
nodes and nodes along both recurrent laryngeal
nerves to the hiatus. The extent of upper abdominal
lymph node dissection included the paracardial, lesser
curvature, left gastric, common hepatic, celiac, and
splenic nodes. Three-field (cervical, mediastinal and
upper abdominal) lymph node dissection was not rou-
tinely performed. However, this procedure was also
performed selectively by surgeons depending on their
preference. The extent of cervical lymph node dissec-
tion included supraclavicular and cervical paraesopha-
geal nodes.
Fig. 2 Histogram of tumor length for the entire cohort of 1435 patients
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Pathological examination
After surgical resection, the esophageal specimen was
opened longitudinally from proximal to distal, extending
this incision along greater curve of stomach if attached.
The anatomical locations of the removed nodes were la-
beled by the operating surgeon. All specimens were fixed
in 10 % formalin overnight, unpinned. and then sent to
pathological examination. Tumor length was measured
to the closest to 1 mm. In addition to tumor length,
pathological details including histology type, differenti-
ation, depth of invasion, lymph node status, vascular in-
vasion, perineural involvement, the number of resected
lymph nodes as well as proximal and distal surgical re-
section margin were reported. Circumferential resection
margin was not routinely examined at our institution.
Data from pathological reports were reviewed retro-
spectively. All patients were restaged based on the 7th
edition of the American Joint Committee on Cancer
TNM staging system [3].
Follow-up
In general, a follow-up examination was performed in
our outpatient department every 3 months for the first
2 years and 6 months thereafter. The routine follow-up
examination included a physical and routine blood ex-
aminations, blood chemistry, measurement of tumor
markers (carcinoembryonic antigen, squamous cell car-
cinoma antigen), radiograph of the chest, and ultra-
sound. Computed tomography of the chest and upper
abdomen were done every 6 months. Endoscopy was
done yearly. Survival time was defined as the period
from the date of surgery till death (including surgical
death and non-cancer related death) or the most recent
follow-up. The duration of follow-up ranged from 1 to
128 months (mean 29.8 months, median 24.0 months).
Statistical analysis
The normally distributed continuous data were de-
scribed as mean ± standard deviation. Categorical data
were describes as counts and proportions. Continuous
variables were compared by student t test. The Pearson
Chi-square test was used to compare categorical vari-
able. The survival time was calculated by the Kaplan-
Meier method, and the log rank test was used to assess
the differences in survival between groups. To determine
an ideal cutoff value for tumor length, the relationship
Fig. 3 Scatter plot of tumor length versus Martingale residuals for the entire cohort of 1435 patients. Patients above the horizontal line (zero)
were at increased risk for death, and those below were at decreased risk for death compared with the expected risk from Cox proportional
hazard regression model. Curved line represents scatterplot smoother. Point at which smoother line cross horizontal line occurs at 4 cm,
indicating this would be an ideal cutoff value of tumor length for these patients
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between tumor length and death from esophageal cancer
was investigated by using a scatter plot of the variable ver-
sus Martingale residuals from a Cox proportional hazard
regression model without the variable of interest. A
smoothed line fit of the scatter was then applied to detect
the ideal cutoff value [16]. Based on the cutoff value, the
tumor length could be treated as a categorical variable.
Univariable Cox regression models were fitted to assess
the relative effect of categorically and continuously coded
tumor length and other clinicopathological variables on
overall survival. The predictive accuracy of each clinico-
pathological variable was determined and was defined
as the ability to discriminate between patients who
died from cancer. The predictive accuracy was assessed
with Harrell's concordance index (C-index) [17], which is
an approximation of area under curve for time-to-event
data. A C-index of 0.5 is equal to chance discrimination
and a C-index of 1.0 represents a perfect discrimination.
Multivariable Cox proportional hazards models were
fitted to identify independent prognostic factors. A back-
ward procedure based on the Akaike Information Criter-
ion (AIC) was used for variable selection.
The parameters of the TNM staging system for
esophageal squamous cell carcinoma (T stage, N stage,
Grade and Location) were selected as a multivariable
base model. Predictive accuracy of the TNM staging
base model was then compared on the addition of tumor
length. Multivariate regression coefficients of the predict-
ive variables were used to develop nomogarms. Model
performance was internally validated by measuring both
discrimination and calibration [17]. Discrimination was
evaluated by C-index as mentioned previously. Calibration
was performed by a calibration curve, in which predicted
versus actual survival are graphically depicted. Both dis-
crimination and calibration were evaluated on this cohort
using bootstrapping with 200 resamples [17]. To assess
the clinical usefulness of prediction models, decision
curve analysis was used by visualizing the net benefits of
prediction models when different threshold probabilities
were considered [18, 19].
For all statistical tests, two sided P < 0.05 was regarded
as statistically significant. All statistical analyses were per-
formed using SPSS version 17.0 (SPSS, Chicago, IL), and
R software version 3.1.3 (https://www.r-project.org/).
Results
Cutoff value of tumor length and patients characteristics
Tumor length ranged from 0.3 to 23.0 cm (mean,
4.5 cm; median, 4.5 cm). The frequency distribution of
tumor length for the entire cohort patients was shown
in Fig. 2. Martingale residuals suggested 4 cm was an ideal
cutoff value for tumor length (Fig. 3). On the basis of this
cutoff value, patients were then divided into two groups
(≤4 cm versus > 4 cm). Comparison of clinicopathological
characteristics between these two groups was shown in
Table 1. Tumor length > 4 cm significantly correlated with
younger age (P = 0.023), male (P < 0.001), lower location
(P = 0.01), increasing T stage (P < 0.001), worse N stage
(P < 0.001), and more resected lymph nodes (P < 0.001),
whereas no association with differentiation, vascular inva-
sion, and perineural involvement could be found.
Univariable and multivariable analysis
Univariable analysis identified both categorically (P < 0.001)
and continuously (P < 0.001) coded tumor length were sig-
nificant prognostic factors for overall survival (Table 2).
The median survival time for patients with tumor length
Table 1 Relationship between tumor length and other
clinicopathological characteristics
Variable Tumor length P value
≤4.0 cm >4.0 cm
All cases 699 736




























Number of resected lymph nodes 24.0 26.5 <0.001
Wu and Chen BMC Cancer  (2016) 16:394 Page 5 of 11
≤ 4 cm was 48 months (95 % CI 40.8–55.2 months),
whereas for those with tumor length > 4 cm it was
27 months (95 % CI 24.3–29.7 months) (P < 0.001) (Fig. 4).
Other significant prognostic factors included sex
(P = 0.025), differentiation (P < 0.001), T stage (P < 0.001), N
stage (P < 0.001), vascular invasion (P = 0.038), and
perineural involvement (P < 0.001) (Table 2). To assess pre-
dictive accuracy for each clinicopathological variable,
C-index was calculated. Among all of the clinicopatho-
logical variables, tumor length was found to be the third
best predictor (58.1 % as a continuous variable, 56.1 % as a
categorical variable) after N stage (67.1 %) and T stage
(60.5 %) (Table 2).
In Cox multivariate analysis, variable selection based
on backward method using AIC was preformed. Both
categorically (P = 0.018) and continuously (P < 0.001)
coded tumor length were independent prognostic factors
for overall survival. Other independent prognostic fac-
tors included age, differentiation, T stage, N stage, and
number of resected lymph nodes. Sex, tumor location,
vascular invasion and perineural involvement did not
have significant impact on overall survival (Table 3).
Table 2 Univariable analysis of overall survival in 1435 patients according to clinicopathological variables
Variable HR 95 % CI P value (C-index) (%)
Age 1.007 0.998–1.015 0.118 52.2
Sex 51.6
Male (reference) 1
Female 0.766 0.608–0.966 0.025
Tumor location 53.2
Upper (reference) 1
Middle 1.318 0.758–2.292 0.328
Lower 1.534 0.882–2.666 0.129
Differentiation 55.4
G1 (reference) 1
G2 2.094 1.622–2.703 <0.001
G3 1.442 1.154–1.802 <0.001
T stage 60.5
T1 (reference) 1
T2 2.253 1.572–3.230 <0.001
T3 3.499 2.545–4.809 <0.001
T4 5.593 3.835–8.156 <0.001
N stage 67.1
N0 (reference) 1
N1 2.001 1.661–2.409 <0.001
N2 3.640 3.007–4.406 <0.001
N3 6.180 4.882–7.823 <0.001
Vascular invasion 51.5
No (reference) 1
Yes 1.224 1.001–1.482 0.038
Perineural involvement 53.8
No (reference) 1
Yes 1.595 1.345–1.891 <0.001
Number of resected lymph nodes 1.002 0.995–1.008 0.577 50.3
Tumor length 56.1
≤ 4.0 cm (reference) 1
> 4.0 cm 1.582 1.368–1.830 <0.001
Tumor length* 1.121 1.088–1.155 <0.001 58.1
*tumor length treated as a continuous variable
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Model comparisons
Three prediction models were built. The first was a
TNM staging base model. The second and the third
were added categorically coded and continuously coded
tumor length to the base model respectively. Results of
three multivariate regression models were listed in
Table 4. Differentiation, T stage, and N stage were inde-
pendent prognostic factors in each of the three models.
Both categorically and continuously coded tumor length
reached statistical significance. Tumor location did not
reach statistical significance in each of the three models.
Three nomograms were developed for predicting overall
survival based on beta coefficients in associated models
(Fig. 5). Model performance was evaluated by internal
validated by bootstrapping. The bootstrap-corrected C-
index for TNM staging base model was 69.4 %. The
addition of categorically and continuously coded tumor
length to the TNM staging base model led to an in-
creased bootstrap-corrected C-index of 69.6 and 69.8 %,
respectively. The calibration curves of the three predic-
tion models were shown in Fig. 6. Each calibration curve
showed good agreement between predicted and actual
outcomes. In the decision curve analysis, three models per-
formed similarly across a wide range threshold probabilities.
Models including tumor length (either categorically or
continuously coded) did not show any net benefit for pre-
dicting overall survival compared to the TNM staging base
model (Fig. 7).
Discussion
Tumor length was demonstrated as an independent prog-
nostic factor for esophageal squamous cell carcinoma in
this study. This result is in agreement with some previous
studies [4–11]. But previous studies did not address the
predictive role of tumor length. Accurate prediction of
cancer prognosis is based on prediction models rather
than on a variable alone. The current TNM staging, as a
gold standard classification system to predict prognosis in
patients [2], is naturally the best option for establishing a
base prediction model. Although it is possible that a sig-
nificant variable in multivariable modeling might not im-
prove discrimination compared with a multivariable base
model, in this cohort, the addition of tumor length did
indeed increase predictive accuracy of TNM staging base
model. Categorically and continuously coded tumor
length increased discrimination of TNM staging base
model from 69.4 to 69.6 and 69.8 % respectively. However,
improved discrimination is not sufficient for a prediction
Fig. 4 Kaplan-Meier curves depicting overall survival according to tumor length
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Table 3 Multivariable analysis of overall survival in 1435 patients according to clinicopathological variables
Categorical tumor length Continuous tumor length
Variable HR 95 % CI P value HR 95 % CI P value
Age 1.011 1.002–1.019 0.014 1.010 1.002–1.019 0.015
Male (reference) 1 0.371
Female 0.896 0.706–1.139 0.908 0.715–1.155 0.342
Upper tumor (reference) 1
Middle tumor 1.150 0.660–2.005 0.622 1.169 0.671–2.038 0.581
Lower tumor 1.113 0.637–1.945 0.708 1.130 0.647–1.974 0.668
G1 (reference) 1
G2 1.503 1.153–1.959 0.003 1.516 1.163–1.976 0.002
G3 1.184 0.942–1.488 0.148 1.180 0.939–1.483 0.157
T1 (reference) 1
T2 1.708 1.182–2.649 0.004 1.666 1.153–2.406 0.006
T3 2.140 1.521–3.009 <0.001 2.081 1.483–2.919 <0.001
T4 2.781 1.855–4.171 <0.001 2.691 1.797–4.028 <0.001
N0 (reference) 1
N1 1.746 1.442–2.116 <0.001 1.716 1.416–2.078 <0.001
N2 2.974 2.422–3.652 <0.001 2.961 2.412–3.636 <0.001
N3 5.128 3.969–6.626 <0.001 5.091 3.939–6.580 <0.001
Vascular invasion 1.113 0.917–1.350 0.278 1.108 0.913–1.344 0.299
Perineural involvement 1.091 0.912–1.305 0.343 1.098 0.918–1.314 0.307
Number of resected lymph nodes 0.987 0.980–0.994 <0.001 0.987 0.980–0.994 <0.001
Tumor length 1.201 1.032–1.403 0.018 1.064 1.026–1.103 <0.001
Table 4 Cox regression models for predicting overall survival
Base model Categorical tumor length Continuous tumor length
Variable HR 95 % CI P value HR 95 % CI P value HR 95 % CI P value
G1 (reference) 1 1 1
G2 1.551 1.193–2.018 0.001 1.548 1.190–2.013 0.001 1.563 1.202–2.034 <0.001
G3 1.191 0.950–1.495 0.130 1.182 0.942–1.484 0.148 1.178 0.939–1.478 0.157
Upper tumor (reference) 1 1 1
Middle tumor 1.192 0.684–2.075 0.535 1.174 0.674–2.044 0.571 1.188 0.682–2.068 0.543
Lower tumor 1.180 0.677–2.056 0.560 1.148 0.658–2.001 0.627 1.156 0.664–2.015 0.608
T1 (reference) 1 1 1
T2 1.757 1.220–2.531 0.002 1.685 1.167–2.433 0.043 1.636 1.033–2.362 0.008
T3 2.296 1.651–3.193 <0.001 2.133 1.522–2.990 <0.001 2.067 1.478–2.892 <0.001
T4 3.066 2.070–4.544 <0.001 2.869 1.924–4.270 <0.001 2.772 1.864–4.123 <0.001
N0 (reference) 1 1 1
N1 1.717 1.418–2.079 <0.001 1.725 1.425–2.089 <0.001 1.700 1.404–2.057 <0.001
N2 2.822 2.304–3.457 <0.001 2.791 2.278–3.418 <0.001 2.777 2.268–3.402 <0.001
N3 4.705 3.670–6.032 <0.001 4.654 3.629–5.968 <0.001 4.618 3.601–5.923 <0.001
Tumor length 1.170 1.005–1.363 0.043 1.058 1.020–1.097 0.002
Bootstrap-corrected C-index (%) 69.4 69.6 69.8
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model to be clinically useful [19]. In decision curve ana-
lysis, three models resulted in similar net benefits for pre-
diction of overall survival, which suggested inclusion of
tumor length did not increase clinical usefulness of TNM
staging system as a prediction model.
Different methods used for deciding cutoff value of
tumor length led to different cutoff values reported in
published series, ranging from 2 to 5 cm [4, 5, 7–9, 11, 12,
14, 15]. Compared to those methods, Martingale residuals
method used in this report might be more scientific be-
cause it comprehensively allows for clinicopathological
characteristics that may impact overall survival [16]. There
were also various types of tumor length used in historical
literature, such as pre-operative endoscopic tumor length
[4, 10], tumor length of fresh specimen measured in oper-
ation [5], and pathological tumor length measured after
operation [9, 12]. Tumor length may vary depending on
different measuring methods. Previous research also has
demonstrated shrinkage of tumor specimen after formalin
fixation [5, 9]. Here pathological tumor length was used
for patients undergoing radical resection because, among
all types of tumor length, it reflected the most accurate
measurement and the minimal observed variation [9, 12].
Tumor location has been included in the current staging
system for esophageal squamous cell carcinoma [3]. In the
present study, however, tumor location was not an inde-
pendent prognostic factor. Many studies focusing on
prognosis of esophageal squamous cell carcinoma had
similar findings too [4, 5, 20], which supports omitting
tumor location as a parameter in the current TNM sta-
ging system. It is noteworthy that the number of resected
lymph nodes was an independent prognostic factor in
multivariable analysis. Number of resected lymph nodes
has been emphasized for its prognostic significance by
many scholars recently [12, 21, 22]. Particularly in node
negative patients number of resected lymph nodes not
only guarantees the quality of esophageal resection, but
also provides accurate staging and better prognosis.
Fig. 5 Nomograms based on Cox models to predict 5-year overall survival. a TNM base model; (b) model combining TNM parameters with
categorically coded tumor length; (c) model combining TNM parameters with continuously coded tumor length. Instructions: The nomogram
allows the users to obtain 5-year overall survival probability corresponding to a patient's clinicopathological characteristics. Locate the patient's
characteristic on the variable row and draw a vertical straight up to the points row to assign a value of points for the variable. Add up the total
points and drop a vertical line from the total points row to obtain 5-year overall survival
Fig. 6 Calibration curves for internal validation of nomograms predicting 5-year overall survival. a TNM base model; (b) model combining TNM
parameters with categorically coded tumor length; (c) model combining TNM parameters with continuously coded tumor length. The x axis
nomogram-predicted probability of overall survival, and the y axis is actual survival. The diagonal line is the reference line indicating perfect
calibration. The solid line indicates performance of the current nomogram
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There are a few limitations of this study. First this study
is limited to its retrospective nature in spite of data col-
lected prospectively. Therefore these results need to be
further confirmed by a prospective study to provide a bet-
ter conclusion. Second, using different surgical procedures
and different types of lymphadenctomy unavoidably leads
to a certain selection bias. Third, measuring errors may
exist in the process of pathological examination. Finally,
although bootstrap method is used for internal validation
of prediction models to obtain unbiased estimates, exter-
nal validation is still needed to determine whether it can
be applied to other patient groups.
Conclusions
In conclusion, tumor length is an independent prognos-
tic factor in patients with squamous cell carcinoma
undergoing radical resection. It increases predictive ac-
curacy of the current TNM staging system for overall
survival. But it does not increase the clinical usefulness
of TNM staging system as a prediction model.
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Fig. 7 Decision curve analysis. The y axis measures net benefit, calculated by summing the benefits (true positive findings) and subtracting the
harms (false positive findings). The grey line is the net benefit for a strategy of treating all patients. The horizontal line is the net benefit of
treating no patients. Dotted line represents net benefit of using a new model. Model A, TNM base model; Model B, the model combining TNM
parameters with categorically coded tumor length; Model C, the model combining TNM parameters with continuously coded tumor length
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